Cesarean Section Complications Clinical Trial
— CALBLOCOfficial title:
Calcium Chloride for Prevention of Blood Loss From Uterine Atony During Intrapartum Cesarean Delivery (CALBLOC): a Double Blind, Randomized, Placebo Controlled Trial and Nested Population Pharmacokinetic and Pharmacodynamic Analysis
NCT number | NCT05027048 |
Other study ID # | 62206 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | April 4, 2022 |
Est. completion date | April 3, 2023 |
Verified date | August 2023 |
Source | Stanford University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Postpartum hemorrhage (PPH) is the leading cause of maternal morbidity and mortality worldwide. Up to 80% of PPH is caused by uterine atony, the failure of the uterine smooth muscle to contract and compress the uterine vasculature after delivery. Laboratory and epidemiological studies show that low extracellular and serum calcium levels, respectively, decrease uterine contractility. A pilot study performed by the investigators supports the hypothesis that intravenous calcium chloride is well tolerated and may have utility in preventing uterine atony. The proposed research will establish the relationship between uterine tone and calcium through a clinical trial with an incorporated pharmacokinetic and pharmacodynamic (PK/PD) study. In a randomized, placebo-controlled, double-blind trial, investigators will establish the effect of 1 gram of intravenous calcium chloride upon quantitative blood loss and uterine tone during cesarean delivery in parturients with high risk of uterine atony. Investigators will concurrently collect serial venous blood samples to measure calcium for PK/PD modeling in this pregnant study cohort. High-quality clinical research and development of novel therapeutics to manage uterine atony are critical to reduce the high maternal morbidity and mortality from PPH.
Status | Completed |
Enrollment | 120 |
Est. completion date | April 3, 2023 |
Est. primary completion date | March 29, 2023 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Patient had a trial of labor for vaginal delivery prior to cesarean - Patient received an oxytocin infusion for labor augmentation or induction prior to cesarean Exclusion Criteria: - renal dysfunction with serum Cr >1.0 mg/dL - known underlying cardiac condition - treatment with digoxin within the last 2 weeks for a maternal or fetal indication - treatment with a calcium channel blocker medication within 24 hours - hypertension necessitating intravenous antihypertensive medication within 24 hours - emergent case in which study participation could in any way impede patient care by the judgement of the obstetrician, anesthesiologist, or bedside nurse |
Country | Name | City | State |
---|---|---|---|
United States | Jessica Ansari | Pacifica | California |
Lead Sponsor | Collaborator |
---|---|
Stanford University |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Quantitative Blood Loss | Standardized volumetric and gravimetric assessment of blood loss during cesarean. Note: will analyze all participants, but planned subgroup analysis will also occur excluding patients with non-atonic reasons for blood loss including hysterotomy extension, placental abruption, cervical or vaginal laceration, etc | measurement occurs at conclusion of operating room case | |
Secondary | Uterine tone numerical rating score | Uterine tone assessment | 2, 7, and 12 minutes after fetal delivery. The absolute 12 minute score as well as delta from 12-2 and 12-7 minute scores will be analyzed | |
Secondary | Second line uterotonic requirement | Yes/no: did the patient require treatment with methylergonovine, carboprost, and/or misoprostol for uterine atony | within 4 hours of delivery | |
Secondary | Fluid requirement | Total crystalloid required during cesarean delivery in mL | Operating room duration, usually 2 hours | |
Secondary | Total oxytocin bolus requirement | Total dose oxytocin bolus during cesarean | Cesarean duration, usually about 2 hours | |
Secondary | Transfusion requirement | Yes/no and total units packed red blood cells | 96 hours of delivery | |
Secondary | Pharmacokinetics of calcium chloride | analyzed in NONMEM using serial venous blood gas ionized calcium levels from willing participants | Within 4 hours of study drug administration | |
Secondary | Pharmacodynamic effect of calcium upon uterine tone NRS | also analyzed in NONMEM | Within 20 minutes of study drug administration | |
Secondary | Percent change in heart rate from baseline | Baseline heart rate recorded as average of first 6 heart rates recorded in operating room. Percent change calculated as measured heart rate minus baseline, divided by baseline. | every 5 minutes for 30 minutes after study drug infusion initiation, compared to baseline | |
Secondary | Percent change in mean arterial blood pressure from baseline | Baseline mean arterial blood pressure recorded as average of first 6 mean arterial blood pressures recorded in operating room. Percent change calculated as measured mean arterial blood pressure minus baseline, divided by baseline. | every 5 minutes for 30 minutes after study drug infusion initiation, compared to baseline | |
Secondary | Total phenylephrine requirement | Total phenylephrine in milligrams administered while in the operating room | Duration of operating room time | |
Secondary | Change in hematocrit from baseline | Measured pre-delivery hematocrit minus measured post-operative day 1 hematocrit. Correction factor of 3 hematocrit points per unit packed red blood cells transfused | 1 day |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04377984 -
Impact of a Strategy Combining Morphine Savings and Anesthesia Technique on the Quality of Post-operative Rehabilitation
|
||
Recruiting |
NCT03248817 -
Phenylephrine Infusion in Cesarean Delivery
|
Phase 4 | |
Completed |
NCT05037383 -
Motion and Viewing Analysis of Surgeons During Minimally Invasive Gynecological Interventions
|
N/A | |
Not yet recruiting |
NCT05933993 -
Mothers Experience of Pain Following Elective Cesarean Section. A Qualitative Study.
|
||
Recruiting |
NCT05021315 -
Vaginal Cleaning Using Povidone Iodine Before CS to Reduce Postoperative Wound Infection
|
Phase 3 | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Recruiting |
NCT06010368 -
Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section
|
Phase 3 | |
Recruiting |
NCT06247852 -
Persistent Pain After Cesarean Delivery - A Danish Multicenter Cohort Study
|
||
Not yet recruiting |
NCT06017076 -
Effect of Preoperative Oral Energy Drinks Compared to Warming Matress on Body Temperature During Combined Spinal-epidural Anesthesia for Elective Cesarean Delivery.
|
N/A | |
Completed |
NCT05005871 -
Comparison of Quadratus Lumborum Intramuscular and Transmuscular in Postoperative Pain
|
N/A | |
Recruiting |
NCT04518176 -
Bilateral Uterine Artery Ligation During the Cesarean Delivery of Twins
|
N/A | |
Not yet recruiting |
NCT04505644 -
Lidocaine Patch Versus Intravenous Lidocaine in Pain Relief After Cesarean Section
|
N/A | |
Not yet recruiting |
NCT03985618 -
The MODE Trial: Planned Caesarean Section Versus Induction of Labour for Women With Class III Obesity
|
N/A | |
Completed |
NCT04046510 -
Comparaison of 3 Protocols of Ocytocin Administration in C Section
|
N/A | |
Completed |
NCT03302039 -
Three Protocols for Phenylephrine Administration in Cesarean Delivery
|
Phase 4 | |
Completed |
NCT03318536 -
Effect of Granisetron on Usage of Sympathomimetics During Caesarean Section
|
||
Recruiting |
NCT03682510 -
B-Lynch Transverse Compression Suture Versus a Sandwich Technique (N&H Technique) for Complete Placenta Previa
|
N/A | |
Recruiting |
NCT03651076 -
Traxi Panniculus Retractor for Cesarean Delivery
|
N/A | |
Not yet recruiting |
NCT06060327 -
Comparing Tranexamic Acid Versus Ecbolics in Preventing Hemorrhage During and After Cesarean Section
|
N/A | |
Completed |
NCT03701048 -
Rectus Musle Reapproximation During Cesarean Section
|
N/A |